VEGFA and endothelial dysfunction: Although these clinical manifestations are likely attributable to sorafenib-induced vascular injury, their progression during regorafenib therapy suggests either a cumulative toxic effect from continuous VEGF pathway inhibition or a worsening of endothelial dysfunction.